Zatolmilast (BPN14770), a phosphodiesterase-4D (PDE4D) inhibitor developed by Tetra Therapeutics, is being investigated as a potential treatment for individuals with FXS. The gene discussed is PDE4D; the disease is fragile X syndrome.